Zacks Small Cap Research on MSN
CRDF: Initiating coverage – combination therapy elicits superior response
CRDF READ THE FULL CRDF RESEARCH REPORT We are initiating coverage of Cardiff Oncology, Inc. (NASDAQ:CRDF) with a valuation of $8.50 per share. This value is based on our estimates for successful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback